Progyny击败了Q3收入估算,并提升了2025年的指导,但内部人出售股票。 Progyny beat Q3 earnings estimates and raised 2025 guidance, but insiders sold shares.

Progyny报告2025年Q3收入丰厚,其中45美元为EPS,3.135亿美元为收入,超过了估计数。 Progyny reported strong Q3 2025 earnings, with $0.45 EPS and $313.35 million in revenue, exceeding estimates. 该公司将其全年2025年EPS指南提高到1.790-1.820美元,Q4指南提高到0.370-0.400美元。 The company raised its full-year 2025 EPS guidance to $1.790–1.820 and Q4 guidance to $0.370–0.400. 首席执行官Peter Anevski购买了79 500股股票,而CFO Mark Livingston出售了21 303股股票。 CEO Peter Anevski bought 79,500 shares, while CFO Mark Livingston sold 21,303 shares. 内幕人士在90天内集体出售了26,698股。 Insiders collectively sold 26,698 shares in 90 days. 分析师维持“机动购买”共识,平均价格目标是27.33美元。 Analysts maintain a "Moderate Buy" consensus with a $27.33 average price target. 该股票的市场上限为22.3亿美元。 The stock has a market cap of $2.23 billion.